|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C07K 16/28 | (2006.01) |
| A61K2039/54 | (2013.01) | ||
| A61P 37/06 | (2006.01) | ||
| C07K2317/72 | (2013.01) | ||
| A61K 39/00 | (2006.01) | ||
| A61K2039/505 | (2013.01) | ||
| A61K2039/545 | (2013.01) | ||
| C07K 16/2803 | (2013.01) | ||
| C07K 16/283 | (2013.01) | ||
| C07K2317/31 | (2013.01) | ||
| C07K2317/76 | (2013.01) | ||
| A61P 1/02 | (2018.01) | ||
| A61P 1/04 | (2018.01) | ||
| A61P 1/16 | (2018.01) | ||
| A61P 1/18 | (2018.01) | ||
| A61P 11/00 | (2018.01) | ||
| A61P 11/02 | (2018.01) | ||
| A61P 13/02 | (2018.01) | ||
| A61P 13/08 | (2018.01) | ||
| A61P 13/12 | (2018.01) | ||
| A61P 15/00 | (2018.01) | ||
| A61P 17/00 | (2018.01) | ||
| A61P 25/00 | (2018.01) | ||
| A61P 27/02 | (2018.01) | ||
| A61P 29/00 | (2018.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61P 37/02 | (2018.01) | ||
| A61P 37/06 | (2018.01) | ||
| A61P 43/00 | (2018.01) | ||
| A61P 5/06 | (2018.01) | ||
| A61P 5/10 | (2018.01) | ||
| A61P 7/00 | (2018.01) | ||
| A61P 9/00 | (2018.01) |
| (11) | Patento numeris | 3468997 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 17731411.9 |
| Europos patento paraiškos padavimo data | 2017-06-08 | |
| (97) | Europos patento paraiškos paskelbimo data | 2019-04-17 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2023-09-13 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2017/036635 |
| Data | 2017-06-08 |
| (87) | Numeris | WO 2017/214452 |
| Data | 2017-12-14 |
| (30) | Numeris | Data | Šalis |
| 201662347419 P | 2016-06-08 | US | |
| 201662399896 P | 2016-09-26 | US | |
| 201662421261 P | 2016-11-12 | US |
| (72) |
ZACK, Debra , US
STONE, John H. , US
PILLAI, Shiv , US
FOSTER, Paul , US
|
| (73) |
Xencor, Inc. ,
465 North Halstead Street
Suite 200, Pasadena, CA 91107,
US
|
| (54) | TREATMENT OF IGG4-RELATED DISEASES WITH ANTI-CD19 ANTIBODIES CROSSBINDING TO CD32B |
| TREATMENT OF IGG4-RELATED DISEASES WITH ANTI-CD19 ANTIBODIES CROSSBINDING TO CD32B |